mTOR Signaling in Cancer Biology

The mechanistic target of rapamycin (mTOR) is a serine/threonine kinase that integrates nutrient, energy and growth-factor signals to coordinate cell growth, proliferation, metabolism and survival. mTOR exists within two distinct multiprotein assemblies: mTOR complex 1 (mTORC1), which senses amino acids and energy status to regulate protein synthesis, lipid biogenesis and autophagy; and mTOR complex 2 (mTORC2), which responds chiefly to growth-factor cues to influence cytoskeletal organisation and full activation of AGC kinases such as AKT. In healthy tissues, tight feedback and cross-talk with upstream regulators—most notably the phosphoinositide 3-kinase (PI3K)/AKT axis and the AMP-activated protein kinase (AMPK)—ensures homeostasis. In cancer, mutations or aberrant expression of pathway components (for example PI3K hyperactivation, PTEN loss or activating alterations in AKT or mTOR itself) result in constitutive mTOR signalling that drives unchecked proliferation, metabolic rewiring, enhanced survival and suppression of autophagy. These defects underpin tumour initiation, progression, metastasis and therapeutic resistance. mTOR inhibitors, ranging from allosteric rapamycin analogues to ATP-competitive kinase inhibitors, have shown clinical benefit in a subset of malignancies, yet intrinsic and acquired resistance limits efficacy. Emerging strategies combine mTOR inhibition with targeted agents or immunotherapies, guided by biomarkers that predict pathway dependency and overcome feedback activation.

Research from Nature Portfolio

No recent Nature Portfolio content available.

mTOR Signaling in Cancer Biology publication trend

The graph below shows the total number of articles in mtor signaling in cancer biology across all publications each year (not limited to Nature Index journals).

Technical terms

mTORC1: A complex sensitive to rapamycin that controls protein synthesis, lipid metabolism and autophagy in response to nutrients and energy status.

mTORC2: A rapamycin-insensitive complex that regulates AKT activation and cytoskeletal organisation downstream of growth factors.

PI3K: A lipid kinase that generates phosphatidylinositol (3,4,5)-trisphosphate to recruit and activate AKT at the plasma membrane.

AKT: A serine/threonine kinase activated by phosphorylation that promotes cell survival, growth and metabolism.

Autophagy: A lysosome-mediated degradative process that recycles intracellular components to maintain energy and nutrient homeostasis.

4E-BP1: A translational repressor phosphorylated by mTORC1; when phosphorylated it releases eIF4E to initiate cap-dependent mRNA translation.

References

1. Multifaceted role of mTOR (mammalian target of rapamycin) signaling pathway in human health and disease. Signal Transduction and Targeted Therapy (2023).
2. PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer. Molecular Cancer (2023).
3. mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges. Cell & Bioscience (2020).